Diagnosis and treatment of bronchiectasis

Archivos de Bronconeumologia

Volumn 44, Issue 11, 2008, Pages 629-640

  Vendrell, Montserrat ^a,b,k   De Gracia, Javier ^b,c   Olveira, Casilda ^d   Martínez, Miguel Ángel ^e   Girón, Rosa ^f   Máiz, Luis ^g   Cantón, Rafael ^g   Coll, Ramon ^h   Escribano, Amparo ⁱ   Solé, Amparo ^j  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ UNIVERSITY OF VALENCIA   (Spain)

^j HOSPITAL UNIVERSITARIO LA FE   (Spain)

^k NONE   (Spain)

more..

Author keywords

Bronchial colonization; Bronchial infection; Bronchial inflammation; Bronchiectasis; Exacerbation

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BRONCHODILATING AGENT; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; COLISTIMETHATE; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; EXPECTORANT AGENT;

ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BRONCHIECTASIS; CHRONIC BRONCHITIS; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; DISEASE COURSE; DISEASE EXACERBATION; HUMAN; PSEUDOMONAS; PULMONARY REHABILITATION; QUALITY OF LIFE; SPUTUM ANALYSIS; TREATMENT OUTCOME; ADULT; AIRWAY OBSTRUCTION; BRONCHITIS; CHILD; CLASSIFICATION; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; HOSPITALIZATION; MULTIMODALITY CANCER THERAPY; PATIENT EDUCATION; PHYSIOTHERAPY; PRACTICE GUIDELINE; PROGNOSIS; RESPIRATORY TRACT INFECTION;

ADULT; AIRWAY OBSTRUCTION; ALGORITHMS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHIECTASIS; BRONCHITIS; BRONCHODILATOR AGENTS; CHILD; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; EXPECTORANTS; HOSPITALIZATION; HUMANS; PATIENT EDUCATION AS TOPIC; PHYSICAL THERAPY MODALITIES; PROGNOSIS; RESPIRATORY TRACT INFECTIONS;

EID: 55949122747     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(08)60117-2     Document Type: Article

References (51)

1. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957-69.
2. Máiz L, Baranda F, Coll R, Prados C, Vendrell M, Escribano A, et al. Normativa del diagnóstico y el tratamiento de la afección respiratoria en la fibrosis quística. Arch Bronconeumol. 2001;37:316-24.
3. De Gracia J, Máiz L, Prados C, Vendrell M, Baranda F, Escribano A, et al. Antibióticos nebulizados en pacientes con fibrosis quística. Med Clin (Barc). 2001;117:233-7.
4. Cantón R, Cobos N, De Gracia J, Baquero F, Honorato J, Gartner S, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect. 2005;11:690-703.
5. Pasteur AC, Helliwell SM, Houghton SJ, Web SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162: 1277-84.
6. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205-9.
7. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138-80.
8. Rosen MJ. Chronic cough due to bronchiectasis. ACCP Evidence-based clinical practice guidelines. Chest. 2006;129:122S-31S.
9. Schünemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006;174:605-14.
10. Kang EY, Miller RR, Müller NL. Bronchiectasis: comparison of preoperative thin section CT and pathologic findings in resected specimens. Radiology. 1995;195:649-54.
11. de Gracia J, Rodrigo MJ, Morell F, Vendrell M, Miravitlles M, Cruz MJ, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med. 1996;153:650-5.
12. de Gracia J, Vendrell M, Álvarez A, Pallisa E, Rodrigo MJ, De la Rosa D, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol. 2004;4:745-53.
13. Rodrigo MJ, Vendrell M, Cruz MJ, Miravitlles M, Pascual C, Morell F, et al. Utility of the antibody response to a conjugated Haemophilus influenzae type b vaccine for diagnosis of primary humoral immunodeficiency. Am J Respir Crit Care Med. 2000; 162:1462-5.
14. Vendrell M, de Gracia J, Rodrigo MJ, Cruz MJ, Álvarez A, García M, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest. 2005;127:197-204.
15. de Gracia J, Mata F, Álvarez A, Casals T, Gatner S, Vendrell M, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax. 2005;60:558-63.
16. Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL, Hazucha M, et al. Primary ciliary dyskinesia. Diagnostic and phenotypic features. Am J Respir Crit Care Med. 2004;169:459-67.
17. Stockley RA, Bayley D, Hill SL, Hill AT, Crooks S, Campbell EJ. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax. 2001;56:366-72.
18. Angrill J, Agustí C, de Celis R, Filella X, Rano A, Elena M, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med. 2001;164:1628-32.
19. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Dowling RB, Cole PJ, et al. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J. 1998;12:820-4.
20. Ferrer A, Llorenç V, Codina G, de Gracia J. Nocardiosis y bronquiectasias. ¿Una asociación frecuente? Enferm Infecc Microbiol Clin. 2005;23:62-6.
21. Maciá MD, Blanquer D, Togores B, Sauleda J, Pérez JL, Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother. 2005;49:3382-6.
22. García-Castillo M, Morosini MI, Valverde A, Almaraz F, Baquero F, Cantón R, et al. Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures. J Antimicrob Chemother. 2007;59:301-4.
23. Morosini MI, García-Castillo M, Loza E, Pérez- Vázquez M, Baquero F, Cantón R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol. 2005;43: 4480-5.
24. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano JB. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1-8.
25. Shah PL, Mawdsley S, Nash K, Cullinan P, Cole PJ, Wilson R. Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis. Eur Respir J. 1999;14:1340-4.
26. Griffith DE, Aksamit T, Brown-Elliot BA, Catanzaro A, Daley C, Gordin F, et al. Diagnosis, treatment and prevention on nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175:367-416.
27. Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J. 2006;28:974-9.
28. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23-30.
29. Olveira G, Padilla A, Olveira C. Soporte nutricional en el paciente con patología pulmonar, enfermedad pulmonar obstructiva crónica y fibrosis quística. In: Bellido D, De Luis D, editors. Manual de metabolismo y nutrición. Madrid: Díaz de Santos, SA; 2006. p. 455-70.
30. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128:739-45.
31. Marco T, Asensio O, Bosque M, de Gracia J, Serra C. Home intravenous antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2000;(4):CD001917.
32. Smyth AR, Tan KH. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2006;(3):CD002009.
33. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest. 2006;130:1503-10.
34. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2006;(1):CD004197.
35. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev. 2007;(2):CD001392.
36. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162:481-5.
37. Vendrell M, de Gracia J. Antibioticoterapia inhalada. Arch Bronconeumol. 1997;33:41-8.
38. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749-56.
39. Davis G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax. 2004;59:540-1.
40. Balfour-Lyn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med. 2006;173:1356-62.
41. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Resp Med. 2006;100: 1623-32.
42. McCool FD, Rosen MJ. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest. 2006;129 1 Suppl:250S-9S.
43. Bradley JM, Moran FM, Elborn JS. Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Resp Med. 2006; 100:191-201.
44. Crockett AJ, Cranston JM, Latimer KM, Alpers JH. Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2001;(1): CD001289.
45. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev. 2006;(2):CD002996.
46. O'Donnell A, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. hDNase study group. Chest. 1998;113:1329-34.
47. Roig J, Llorente JL, Ortega FJ, Orriols R. Manejo de la hemoptisis amenazante. Available from: www.separ.es/publicaciones/ normativas_y_procedimientos.html
48. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745-55.
49. Balkanli K, Genç O, Dakak M, Gürkök S, Gözübüyük A, Caylak H, et al. Surgical management of bronchiectasis: analysis and short-term results in 238 patients. Eur J Cardiothorac Surg. 2003; 24:699-702.
50. Lavery K, O'Neill B, Elborn JS, Reilly J, Bradley JM. Self-management in bronchiectasis: the patients' perspective. Eur Respir J. 2007;29:541-7.
51. Eastham KM, Fall AJ, Mitchell L, Spencer DA. The need to redefine non-cystic fibrosis bronchiectasis in childhood. Thorax. 2004;59:324-7.